[go: up one dir, main page]

DK0721455T3 - Tetrahydropyridin-(eller 4-hydroxypiperidin)alkylazoler med en affinitet for sigma og/eller 5-HT1A-receptorer - Google Patents

Tetrahydropyridin-(eller 4-hydroxypiperidin)alkylazoler med en affinitet for sigma og/eller 5-HT1A-receptorer

Info

Publication number
DK0721455T3
DK0721455T3 DK95928478T DK95928478T DK0721455T3 DK 0721455 T3 DK0721455 T3 DK 0721455T3 DK 95928478 T DK95928478 T DK 95928478T DK 95928478 T DK95928478 T DK 95928478T DK 0721455 T3 DK0721455 T3 DK 0721455T3
Authority
DK
Denmark
Prior art keywords
hydroxypiperidine
tetrahydropyridine
sigma
affinity
ht1a receptors
Prior art date
Application number
DK95928478T
Other languages
English (en)
Inventor
Ramon Merce-Vidal
Jordi Frigola-Constansa
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of DK0721455T3 publication Critical patent/DK0721455T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK95928478T 1994-07-29 1995-07-26 Tetrahydropyridin-(eller 4-hydroxypiperidin)alkylazoler med en affinitet for sigma og/eller 5-HT1A-receptorer DK0721455T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9409443A FR2723091B1 (fr) 1994-07-29 1994-07-29 Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
PCT/EP1995/002978 WO1996004287A1 (fr) 1994-07-29 1995-07-26 Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a

Publications (1)

Publication Number Publication Date
DK0721455T3 true DK0721455T3 (da) 2003-04-07

Family

ID=9465902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95928478T DK0721455T3 (da) 1994-07-29 1995-07-26 Tetrahydropyridin-(eller 4-hydroxypiperidin)alkylazoler med en affinitet for sigma og/eller 5-HT1A-receptorer

Country Status (22)

Country Link
US (2) US5731331A (da)
EP (1) EP0721455B9 (da)
JP (2) JP4035787B2 (da)
KR (1) KR100389785B1 (da)
CN (1) CN1120167C (da)
AT (1) ATE229530T1 (da)
AU (1) AU712479B2 (da)
BR (1) BR9506292A (da)
CA (1) CA2172986A1 (da)
CZ (1) CZ293123B6 (da)
DE (1) DE69529142T2 (da)
DK (1) DK0721455T3 (da)
FI (1) FI116386B (da)
FR (1) FR2723091B1 (da)
HU (1) HU220088B (da)
NO (1) NO309379B1 (da)
NZ (1) NZ291172A (da)
PL (1) PL183766B1 (da)
PT (1) PT721455E (da)
RU (1) RU2168507C2 (da)
WO (1) WO1996004287A1 (da)
ZA (1) ZA956314B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
FR2742052B1 (fr) * 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
GB9613423D0 (en) * 1996-06-26 1996-08-28 Lilly Industries Ltd Pharmaceutical compounds
HUP9602763A3 (en) * 1996-10-09 1999-05-28 Egyt Gyogyszervegyeszeti Gyar 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same
US5919802A (en) * 1997-12-05 1999-07-06 Princeton University Methods of preventing and/or treating temporal lobe epilepsy
ES2151828B1 (es) * 1998-07-10 2001-08-16 Esteve Labor Dr Empleo de derivados de tetrahidropiridinas (ohidroxi-piperidinas)-b utilazoles en la elaboracion de un medicamento para el tratamiento del dolor.
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1781619B1 (en) 2004-08-27 2011-08-17 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
ES2251316B1 (es) * 2004-10-14 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Inhibidores del receptor sigma.
ES2251317B1 (es) * 2004-10-14 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Inhibidores del receptor sigma.
KR100895998B1 (ko) * 2007-05-11 2009-05-07 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
JP5514716B2 (ja) * 2007-05-11 2014-06-04 コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物
KR100871077B1 (ko) * 2007-05-11 2008-11-28 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
KR100893394B1 (ko) * 2007-05-11 2009-04-17 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
MX388468B (es) 2009-12-04 2025-03-20 Sunovion Pharmaceuticals Inc Compuestos multicíclicos y métodos de uso de los mismos.
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
MY199446A (en) 2016-07-29 2023-10-28 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sumitomo Pharma America, Inc. Methods of treating schizophrenia
CN109280030B (zh) * 2017-07-19 2022-04-22 江苏恩华药业股份有限公司 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
MY208150A (en) 2018-02-16 2025-04-18 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
JP7781768B2 (ja) 2020-04-14 2025-12-08 スミトモ・ファーマ・アメリカ・インコーポレイテッド 神経学的および精神障害の治療方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509153A (en) * 1967-03-24 1970-04-28 Miles Lab 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
ES378315A1 (es) * 1969-04-11 1972-06-01 Robins Co Inc A H Un procedimiento para la preparacion de 1 - (omega-susti- tuido-alcohil)-2-metilbenzimidazoles.
JPS5011395B1 (da) * 1970-12-29 1975-04-30
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US3981881A (en) * 1975-08-14 1976-09-21 E. R. Squibb & Sons, Inc. 2-[(4-Phenyl-tetrahydropyridinyl)alkyl]-1H-isoindole-1,3(2H)-diones
US3994904A (en) * 1976-03-08 1976-11-30 Miles Laboratories, Inc. 3-Substituted -5-phenyl-5-pyridyl hydantoins
JPS5746983A (en) * 1980-09-04 1982-03-17 Eisai Co Ltd Theophylline derivative and its preparation
JPS58150511A (ja) * 1982-03-02 1983-09-07 Eisai Co Ltd テオフイリン誘導体を有効成分とする脳循環代謝改善剤
DE3364234D1 (en) * 1982-03-02 1986-07-31 Eisai Co Ltd Antiphlogistic/antipyretic/analgesic pharmaceutical compositions containing theophylline derivatives as active ingredient
US4539407A (en) * 1983-12-13 1985-09-03 American Home Products Corporation β-Carboline anticonvulsants
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
US4754038A (en) * 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
US5296487A (en) * 1990-01-02 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives and their preparation
EP0436157B1 (en) * 1990-01-02 1995-08-23 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives and their preparation
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
JP3198117B2 (ja) * 1990-02-07 2001-08-13 サントリー株式会社 ピロロアゼピン誘導体
JPH04211059A (ja) * 1990-03-05 1992-08-03 Shionogi & Co Ltd 新規なテトラヒドロピリジン誘導体
US5149817A (en) * 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
FR2671972B1 (fr) * 1991-01-25 1995-03-03 Esteve Labor Dr Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives.
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
JP3219281B2 (ja) * 1991-04-03 2001-10-15 聰 竹尾 心筋保護剤
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
WO1995003298A1 (en) * 1993-07-19 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST
US5411960A (en) * 1993-12-09 1995-05-02 Bayer Aktiengesellschaft Substituted pyrroloanthracenes and -diones
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles

Also Published As

Publication number Publication date
KR100389785B1 (ko) 2003-10-04
PL183766B1 (pl) 2002-07-31
US5731331A (en) 1998-03-24
US6232329B1 (en) 2001-05-15
FI961412L (fi) 1996-03-28
PT721455E (pt) 2003-04-30
ATE229530T1 (de) 2002-12-15
MX9601191A (es) 1997-12-31
PL313716A1 (en) 1996-07-22
CN1166173A (zh) 1997-11-26
EP0721455A1 (fr) 1996-07-17
HU9600815D0 (en) 1996-07-29
JP2007051154A (ja) 2007-03-01
HU220088B (hu) 2001-10-28
AU3222595A (en) 1996-03-04
FI961412A0 (fi) 1996-03-28
RU2168507C2 (ru) 2001-06-10
FR2723091B1 (fr) 1996-11-08
JPH09503230A (ja) 1997-03-31
CN1120167C (zh) 2003-09-03
BR9506292A (pt) 1997-08-12
NO309379B1 (no) 2001-01-22
JP4035787B2 (ja) 2008-01-23
WO1996004287A1 (fr) 1996-02-15
CZ293123B6 (cs) 2004-02-18
AU712479B2 (en) 1999-11-11
EP0721455B1 (fr) 2002-12-11
FR2723091A1 (fr) 1996-02-02
DE69529142T2 (de) 2003-09-25
NZ291172A (en) 1998-02-26
NO961207D0 (no) 1996-03-25
EP0721455B9 (fr) 2005-04-20
FI116386B (fi) 2005-11-15
NO961207L (no) 1996-05-29
HUT75645A (en) 1997-05-28
CA2172986A1 (fr) 1996-02-15
KR960704900A (ko) 1996-10-09
ZA956314B (en) 1996-03-25
DE69529142D1 (de) 2003-01-23
CZ92696A3 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
DK0721455T3 (da) Tetrahydropyridin-(eller 4-hydroxypiperidin)alkylazoler med en affinitet for sigma og/eller 5-HT1A-receptorer
IL90101A0 (en) Benzoyprido piperidine,piperidylene and piperazine compounds,compositions,methods of manufacture and methods of use
YU29892A (sh) Postupak za stereoselektivno dobijanje supstituisanih piperidina
KR860004918A (ko) 트리사이클로 화합물의 제조방법
DE69716116D1 (de) VERFAHREN ZUR HERSTELLUNG VON 3-KETO-7alpha-ALKOXYCARBONYL- delta4,5-STEROIDEN SOWIE ZWISCHENPRODUKTE
ATE166650T1 (de) Spiroazacyclischderivate als substanz p antagonisten
ATE248852T1 (de) Sterolderivate für die regulierung der meiose
ATE211732T1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
ATE137761T1 (de) 4-substituiertes 17-beta-(cyclopropyl-amino)- androst-5-en-3-beta-ol und seine derivate, verwendbar als inhibitoren der c17-20-lyase
DE69027262D1 (de) 4-Substitutiertes 17-beta-(Cyclopropyloxy)androst-5-en-3-beta-ol und seine Derivate, verwendbar als Inhibitoren der C17-20-Lyase
YU63696A (sh) Novi fenilamidin-derivati, postupci za njihovo pripremanje i njihova primena kao lekova
ATE244712T1 (de) Piperazino-derivative als neurokininantagonisten
FI844232L (fi) Purinderivat.
NO983860L (no) Nye triazolopuriner, fremgangsmÕte for deres fremstilling og deres anvendelse som legemidler
ZA909774B (en) Substituted cyclohexenes as central nervous system agents
ES8602676A1 (es) Un procedimiento para la preparacion de nuevos derivados de pirrolo-(2,1-a)isoquilonina.
ES2117934A1 (es) Tetrahidropiridinas (0 4-hidroxipiperidinas) alquilazoles.
TW367320B (en) Novel aryl compounds having CNS activity, process for their preparation and their use as medicaments